miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases

Experimental Cell Research

Volumn 338, Issue 1, 2015, Pages 89-96

  Qu, Bo ^a   Xia, Xun ^a   Yan, Ming ^b   Gong, Kai ^a   Deng, Shaolin ^a   Huang, Gang ^a   Ma, Zehui ^a   Pan, Xianming ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone resorption; miR 218; Osteoclastogenesis; Osteopenic diseases; P38MAPK pathway

Indexed keywords

CATHEPSIN K; MESSENGER RNA; MICRORNA; MICRORNA 218; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN; NFATC1 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MOTION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLIC BONE DISEASE; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; BONE DISEASES, METABOLIC; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED ICR; MICRORNAS; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RNA INTERFERENCE;

EID: 84942194739     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.07.023     Document Type: Article

References (30)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int. J. Med. Sci. 2012, 9:825.
3. Fischer A., Böhm C., Saferding V., Goncalves-Alves E., Kreindl R., Koenders M., van den Berg W., Rothe T., Krönke G., Dudziak D. 4.8 Role of Toll-like receptor 9 in the pathogenesis of inflammatory autoimmune arthritis and osteoclast activation. Ann. Rheum. Dis. 2014, 73:A59-A60.
4. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 1999, 27:1229-1241.
5. Lee J., Youn B.U., Kim K., Kim J.H., Lee D.H., Seong S., Kim I., Han S.H., Che X., Choi J.Y. Mst2 controls bone homeostasis by regulating osteoclast and osteoblast differentiation. J. Bone Miner. Res. 2015, 10.1002/jbmr.2503.
6. Amend S.R., Uluckan O., Hurchla M., Leib D., Veis Novack D., Silva M., Frazier W., Weilbaecher K.N. Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J. Bone Miner. Res. 2015, 30:106-115.
7. Siemens H., Jackstadt R., Kaller M., Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013, 4:1399.
8. Shenoy A., Blelloch R.H. Regulation of microRNA function in somatic stem cell proliferation and differentiation. Nat. Rev. Mol. Cell Biol. 2014, 15:565-576.
9. van Wijnen A.J., van de Peppel J., van Leeuwen J.P., Lian J.B., Stein G.S., Westendorf J.J., Oursler M.-J., Im H.-J., Taipaleenmäki H., Hesse E. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 2013, 11:72-82.
10. Tang P., Xiong Q., Ge W., Zhang L. The role of MicroRNAs in osteoclasts and osteoporosis. RNA Biol. 2014, 11:1355-1363.
11. Liu J., Dang L., Li D., Liang C., He X., Wu H., Qian A., Yang Z., Au D.W., Chiang M.W. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials 2015, 52:148-160.
12. Chen C., Cheng P., Xie H., Zhou H.D., Wu X.P., Liao E.Y., Luo X.H. MiR-503 regulates osteoclastogenesis via targeting RANK. J. Bone Miner. Res. 2014, 29:338-347.
13. Hassan M.Q., Maeda Y., Taipaleenmaki H., Zhang W., Jafferji M., Gordon J.A., Li Z., Croce C.M., Van Wijnen A.J., Stein J.L. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 2012, 287:42084-42092.
14. Liu Y., Huang T., Zhao X., Cheng L. MicroRNAs modulate the Wnt signaling pathway through targeting its inhibitors. Biochem. Biophys. Res. Commun. 2011, 408:259-264.
15. Kim M.H., Ryu S.Y., Choi J.S., Min Y.K., Kim S.H. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J. Cell. Physiol. 2009, 221:618-628.
16. Ory S., Brazier H., Pawlak G., Blangy A. Rho GTPases in osteoclasts: orchestrators of podosome arrangement. Eur. J. Cell Biol. 2008, 87:469-477.
17. Boyce B.F., Rosenberg E., de Papp A.E., Duong L.T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur. J. Clin. Investig. 2012, 42:1332-1341.
18. Henriksen K., Karsdal M.A., Martin T.J. Osteoclast-derived coupling factors in bone remodeling. Calcif. Tissue Int. 2014, 94:88-97.
19. Baxter D., McInnes I.B., Kurowska-Stolarska M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol. Cell Biol. 2012, 90:288-292.
20. Hayden R.S., Fortin J.P., Harwood B., Subramanian B., Quinn K.P., Georgakoudi I., Kopin A.S., Kaplan D.L. Cell-tethered ligands modulate bone remodeling by osteoblasts and osteoclasts. Adv. Funct. Mater. 2014, 24:472-479.
21. Zhang T., Wang J., Zhou X., Liang R., Bai Q., Yang L., Gu H., Gao G., Dong B., Zhu H., Chen X. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. J. Cell. Biochem. 2014, 115:1918-1927.
22. To T.T., Witten P.E., Renn J., Bhattacharya D., Huysseune A., Winkler C. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. Development 2012, 139:141-150.
23. Xiong J., O'Brien C.A. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 2012, 27:499-505.
24. Das S., Crockett J.C. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des. Dev. Ther. 2013, 7:435.
25. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., Delmas P., Zoog H.B., Austin M., Wang A. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl. J. Med. 2009, 361:756-765.
26. Vaananen H., Zhao H., Mulari M., Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 2000, 113:377-381.
27. Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., Zhao L., Nagy T.R., Peng X., Hu J. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 2009, 15:757-765.
28. Tian B., Qin A., Shao Z., Jiang T., Zhai Z., Li H., Tang T., Jiang Q., Dai K., Zheng M. OA-4 inhibits osteoclast formation and bone resorption via suppressing RANKL induced P38 signaling pathway. Curr. Med. Chem. 2014, 21:641-649.
29. Mbalaviele G., Anderson G., Jones A., De Ciechi P., Settle S., Mnich S., Thiede M., Abu-Amer Y., Portanova J., Monahan J. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J. Pharmacol. Exp. Ther. 2006, 317:1044-1053.
30. Kwak H.B., Lee B.K., Oh J., Yeon J.-T., Choi S.-W., Cho H.J., Lee M.S., Kim J.-J., Bae J.-M., Kim S.H. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 2010, 46:724-731.